Cure Alzheimer's Fund Cure Alzheimer's Fund

Ali Ezzati, M.D.

Associate Professor of Neurology; Director, Neuroinformatics Program; Department of Neurology, University of California, Irvine

Dr. Ali Ezzati is a board-certified neurologist and the Director of the Neuroinformatics Program at the University of California, Irvine (UCI). He obtained his medical degree from Shahid Beheshti University in Iran and went on to complete two post-doctoral research fellowships at Massachusetts General Hospital and Albert Einstein College of Medicine. Following this, he completed his internship and neurology residency at Montefiore Medical Center and Albert Einstein College of Medicine, and subsequently spent five years as faculty at Einstein before joining UCI.

With expertise in neuroinformatics and data science, Dr. Ezzati has extensive clinical and research experience in cognitive neurology, Alzheimer’s disease, and related dementias. He has made significant contributions to Alzheimer’s disease research in various capacities, including as a postdoctoral fellow, resident, faculty member, and investigator. His expertise encompasses the design and execution of clinical-epidemiologic studies, as well as the utilization of big biomedical data, including neuropsychological data, neuroimaging, genomics, and digital and biological biomarkers in the field of Alzheimer’s disease.

Dr. Ezzati’s notable contributions focus on the application of artificial intelligence (AI) and machine learning modeling, particularly in the neuroepidemiology of aging and dementia. He has explored the interplay between cognition, Alzheimer’s biomarkers (such as biofluid and neuroimaging markers), and Alzheimer’s risk factors (such as vascular disease, neuropsychiatric comorbidities, and psychosocial factors).

His research receives support from esteemed organizations such as the National Institute of Health, Cure Alzheimer’s Fund, Alzheimer’s Association, and investigator-initiated studies from the industry.

To learn more, visit Dr. Ezzati’s social media and LinkedIn profile pages.

 

Related Research:

Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16 Application of Machine Learning Methods in Alzheimer’s Disease Clinical Trials Ali Ezzati Richard Lipton 2020-02-18

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Project Description Researchers Funding
Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) 2024

$201,250

Application of Machine Learning Methods in Alzheimer’s Disease Clinical Trials 2020, 2022

$200,000

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Ghanbarian, E., Khorsand, B., Petersen, K. K., Nallapu, B. T., Sajjadi, S. A., Lipton, R. B., Ezzati, A., & Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid inflammatory cytokines as prognostic indicators for cognitive decline across Alzheimer’s disease spectrum, Journal of Alzheimer's Disease, April 22, 2025, Read More

Nallapu, B. T., Petersen, K. K., Qian, T., Demirsoy, I., Ghanbarian, E., Davatzikos, C., Lipton, R. B., Ezzati, A., & Alzheimer's Disease Neuroimaging Initiative A Machine Learning Approach to Predict Cognitive Decline in Alzheimer Disease Clinical Trials, Neurology, March 25, 2025, Read More

Petersen, K. K., Nallapu, B. T., Lipton, R. B., Grober, E., & Ezzati, A. MRI-guided clustering of patients with mild dementia due to Alzheimer’s disease using self-organizing maps, NeuroImage Reports, January 30, 2025, Read More

Nallapu, B. T., Petersen, K. K., Lipton, R. B., Davatzikos, C., Ezzati, A., & Alzheimer’s Disease Neuroimaging Initiative Plasma Biomarkers as Predictors of Progression to Dementia in Individuals with Mild Cognitive Impairment, Journal of Alzheimer's Disease, March 5, 2024, Read More

Nallapu, B. T., Petersen, K. K., Lipton, R. B., Grober, E., Sperling, R. A., & Ezzati, A. Association of Alcohol Consumption with Cognition in Older Population: The A4 Study, Journal of Alzheimer's Disease, June 13, 2023, Read More

Grober, E., Petersen, K. K., Lipton, R. B., Hassenstab, J., Morris, J. C., Gordon, B. A., & Ezzati, A. Association of Stages of Objective Memory Impairment With Incident Symptomatic Cognitive Impairment in Cognitively Normal Individuals, Neurology, April 19, 2023, Read More

Wang, C., Nester, C. O., Chang, K., Rabin, L. A., Ezzati, A., Lipton, R. B., & Katz, M. J. Tracking cognition with the T-MoCA in a racially/ethnically diverse older adult cohor, Alzheimer's & Dementia, March 8, 2023, Read More

Petersen, K. K., Ezzati, A., Lipton, R. B., Gordon, B. A., Hassenstab, J., Morris, J. C., & Grober, E. Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease, Journal of Prevention of Alzheimer's Disease, November 3, 2022, Read More

Rubin-Norowitz, M., Lipton, R. B., Petersen, K., Ezzati, A., & Alzheimer’s Disease Neuroimaging Initiative Association of Depressive Symptoms and Cognition in Older Adults Without Dementia Across Different Biomarker Profiles, Journal of Alzheimer's disease, June 28, 2022, Read More

Petersen, K. K., Lipton, R. B., Grober, E., Davatzikos, C., Sperling, R. A., & Ezzati, A. Predicting Amyloid Positivity in Cognitively Unimpaired Older Adults A Machine Learning Approach Using A4 Data, Neurology, June 14, 2022, Read More

Grober, E., Lipton, R. B., Sperling, R. A., Papp, K. V., Johnson, K. A., Rentz, D. M., Veroff, A. E., Aisen, P. S., & Ezzati, A. Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI The A4 Study, Neurology, March 29, 2022, Read More

Ezzati, A., Davatzikos, C., Wolk, D. A., Hall, C. B., Habeck, C., & Lipton, R. B. Application of predictive models in boosting power of Alzheimer’s disease clinical trials: A post hoc analysis of phase 3 solanezumab trials, Alzheimer's & Dementia, March 14, 2022, Read More

Petersen, K. K., Grober, E., Lipton, R. B., Sperling, R. A., Buckley, R. F., Aisen, P. S., & Ezzati, A. Impact of sex and APOE ε4 on the association of cognitionand hippocampal volume in clinically normal, amyloid positive adults, Alzheimer's & Dementia, February 9, 2022, Read More

Ezzati, A., Abdulkadir, A., Jack, C. R., Jr, Thompson, P. M., Harvey, D. J., Truelove-Hill, M., Sreepada, L. P., Davatzikos, C., Alzheimer's Disease Neuroimaging Initiative, & Lipton, R. B. Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer’s disease dementia, Alzheimer's & Dementia, November 17, 2021, Read More

Lou, C., Habes, M., Illenberger, N. A., Ezzati, A., Lipton, R. B., Shaw, P. A., Stephens-Shields, A. J., Akbari, H., Doshi, J., Davatzikos, C., & Shinohara, R. T. Leveraging machine learning predictive biomarkers to augment the statistical power of clinical trials with baseline magnetic resonance imaging, Brain Communications, November 3, 2021, Read More

Ezzati, A., Zammit, A. R., & Lipton, R. B. Comparing Performance of Different Predictive Models in Estimating Disease Progression in Alzheimer Disease, Alzheimer Disease and Associated Disorders, August 16, 2021, Read More

Lam, S., Lipton, R. B., Harvey, D. J., Zammit, A. R., Ezzati, A., & Alzheimer's Disease Neuroimaging Initiative White matter hyperintensities and cognition across different Alzheimer’s biomarker profiles., Journal of the American Geriatrics Society, April 23, 2021, Read More

Back to Our Researchers